Risks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled Trials

The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis

(2015) Kim Donoghue et al.   ADDICTION

Clinical relevance of nalmefene versus placebo in alcohol treatment: Reduction in mortality risk

(2015) Michael Roerecke et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

(2015) Matt Stevenson et al.   PHARMACOECONOMICS

Methods to Analyze Treatment Effects in the Presence of Missing Data for a Continuous Heavy Drinking Outcome Measure When Participants Drop Out from Treatment in Alcohol Clinical Trials

(2014) Katie Witkiewitz et al.   ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH

How to Use a Subgroup Analysis

(2014) Xin Sun et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Pharmacotherapy for Adults With Alcohol Use Disorders in Outpatient Settings

(2014) Daniel E. Jonas et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study

(2014) Wim van den Brink et al.   JOURNAL OF PSYCHOPHARMACOLOGY

The cost-effectiveness and public health benefit of nalmefene added to psychosocial support for the reduction of alcohol consumption in alcohol-dependent patients with high/very high drinking risk levels: a Markov model

(2014) P. Laramee et al.   BMJ Open

Bad medicine: nalmefene in alcohol misuse

(2014) D. Spence   BMJ-British Medical Journal

German evaluation says new drug for alcohol dependence is no better than old one

(2014) N. Stafford   BMJ-British Medical Journal

Nalmefene in alcohol misuse: junk evaluation by the European Medicines Agency

(2014) A. Braillon   BMJ-British Medical Journal

Alcohol Harm Reduction: Corporate Capture of a Key Concept

(2014) Jim McCambridge et al.   PLOS MEDICINE

Efficacy of As-Needed Nalmefene in Alcohol-Dependent Patients with at Least a High Drinking Risk Level: Results from a Subgroup Analysis of Two Randomized Controlled 6-Month Studies

(2013) W. van den Brink et al.   ALCOHOL AND ALCOHOLISM

Naltrexone and Nalmefene: Any Meaningful Difference?

(2013) Robert M. Swift   BIOLOGICAL PSYCHIATRY

A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence

(2013) Antoni Gual et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Extending the Treatment Options in Alcohol Dependence: A Randomized Controlled Study of As-Needed Nalmefene

(2012) Karl Mann et al.   BIOLOGICAL PSYCHIATRY

Efficacy of Extended-Release Naltrexone in Patients with Relatively Higher Severity of Alcohol Dependence

(2011) Helen M. Pettinati et al.   ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH

Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders

(2009) Jürgen Rehm et al.   LANCET

The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

(2009) Alessandro Liberati et al.   PLOS MEDICINE